Zcchc4, zinc finger CCHC domain-containing protein 4, is an N6 -methyladenosine (m6A) RNA methyltransferase. It mainly methylates human 28S rRNA, and this rRNA m6A modification is significant for translation [4,5,6]. Zcchc4 also has an impact on various biological processes related to cancer, such as affecting apoptosis and chemoresistance pathways [1].

In cancer research, knockout of Zcchc4 in HCC cells reduces tumor growth in vivo and enhances the antitumor effect of DNA -damage agents, as it promotes the interaction between a lncRNA AL133467.2 and γH2AX to enhance chemosensitivity [1]. In osteosarcoma, knockdown of Zcchc4 in an animal model reduces tumor growth and metastases, as it normally promotes the disease progression by upregulating ITGB1 [2]. In esophageal cancer, down -regulation of Zcchc4 in vivo inhibits cancer progression and reduces cisplatin resistance, as it leads to increased ROS, S -phase arrest, and enhanced apoptosis [3].

In summary, Zcchc4 is crucial for rRNA methylation and translation. Its knockout or down -regulation in various cancer models reveals its promoting role in cancer progression and chemoresistance. These findings suggest Zcchc4 as a potential target for improving cancer chemotherapy, contributing to a better understanding of cancer -related biological processes [1,2,3].